The efficacy and safety of nivolumab in the treatment of advanced melanoma: A meta-analysis of clinical trials

OncoTargets and Therapy

Volumn 9, Issue , 2016, Pages 1571-1578

  Jin, Conghui ^a   Zhang, Xunlei ^a   Zhao, Kuiling ^a   Xu, Jun ^a   Zhao, Min ^a   Xu, Xiaohong ^a  

^a Nantong Tumor Hospital   (China)

Author keywords

Advanced melanoma; Meta analysis; Nivolumab

Indexed keywords

IPILIMUMAB; NIVOLUMAB;

ADVANCED CANCER; ARTICLE; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HIGH RISK PATIENT; HUMAN; MELANOMA; META ANALYSIS; NAUSEA; OUTCOME ASSESSMENT; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; SURVIVAL RATE; SYSTEMATIC REVIEW; VOMITING;

EID: 84961266555     PISSN: None     EISSN: 11786930     Source Type: Journal    
DOI: 10.2147/OTT.S96762     Document Type: Article

References (35)

1. ®): melanoma version 3.2015. NCCN; 2015. Available from: http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site. Accessed February 3, 2016.
2. Johnston KM, McPherson E, Osenenko K, et al. Cost-effectiveness of therapies for melanoma. Expert Rev Pharmacoecon Outcomes Res. 2015;15(2):229–242.
3. Fox MC, Lao CD, Schwartz JL, et al. Management options for metastatic melanoma in the era of novel therapies: a primer for the practicing dermatologist: part II: management of stage IV disease. J Am Acad Dermatol. 2013;68(1):13.e1–13.
4. World Health Organization [homepage on the Internet]. Ultraviolet radiation and the INTERSUN Programme. WHO; 2012. Available from: http://www.who.int/uv/en/. Accessed February 3, 2016.
5. Dummer R, Hauschild A, Guggenheim M, et al. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23 Suppl 7:vii86–vii91.
6. Niezgoda A, Niezgoda P, Czajkowski R. Novel Approaches to Treatment of Advanced Melanoma: A Review on Targeted Therapy and Immunotherapy. Biomed Res Int. 2015;2015:851387.
7. Saranga-Perry V, Ambe C, Zager JS, Kudchadkar RR. Recent developments in the medical and surgical treatment of melanoma. CA Cancer J Clin. 2014;64(3):171–185.
8. Weide B, Di Giacomo AM, Fonsatti E, Zitvogel L. Immunologic correlates in the course of treatment with immunomodulating antibodies. Semin Oncol. 2015;42(3):448–458.
9. Luke JJ, Ott PA. PD-1 pathway inhibitors: the next generation of immunotherapy for advanced melanoma. Oncotarget. 2015;6(6):3479–3492.
10. Antonia SJ, Larkin J, Ascierto PA. Immuno-oncology combinations: a review of clinical experience and future prospects. Clin Cancer Res. 2014;20(24):6258–6268.
11. Shih K, Arkenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies. Drugs. 2014;74(17):1993–2013.
12. Tsai KK, Daud AI. The role of anti-PD-1/PD-L1 Agents in Melanoma: Progress to Date. Drugs. 2015;75(6):563–575.
13. McArthur GA, Chapman PB, Robert C, et al. Safety and efficacy of vemurafenib in BRAF V600E and BRAF V600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol. 2014;15(3):323–332.
14. Flaherty KT, Robert C, Hersey P, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107–114.
15. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358–365.
16. Sosman JA, Kim KB, Schuchter L, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med. 2012;366(8):707–714.
17. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507–2516.
18. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711–723.
19. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517–2526.
20. Wang C, Thudium KB, Han M, et al. In vitro characterization of the anti-PD-1 antibody nivolumab, BMS-936558, and in vivo toxicology in non-human primates. Cancer Immunol Res. 2014;2(9):846–856.
21. Haanen JB, Thienen HV, Blank CU. Toxicity patterns with immunomodulating antibodies and their combinations. Semin Oncol. 2015;42(3):423–428.
22. Topalian SL, Mario S, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020–1030.
23. Topalian SL, Drake CG, Pardoll DM. Targeting the PD-1/B7-H1 (PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol. 2012;24(2):207–212.
24. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373(1):23–34.
25. Postow MA, Chesney J, Pavlick AC, et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med. 2015;372(21):2006–2017.
26. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320–330.
27. Weber JS, D’Angelo SP, Minor D, et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375–384.
28. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Lancet. 1999;354(9193):1896–1900.
29. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration; 2011. Available from: http://www.cochrane-handbook.org. Accessed March 2, 2016.
30. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228–247.
31. Thompson JA. Treatment options expanding for advanced melanoma. J Natl Compr Canc Netw. 2015;13(5 Suppl):673–675.
32. Delyon J, Maio M, Lebbé C. The ipilimumab lesson in melanoma: achieving long-term survival. Semin Oncol. 2015;42(3):387–401.
33. Delyon J, Mateus C, Lefeuvre D, et al. Experience in daily practice with ipilimumab for the treatment of patients with metastatic melanoma: an early increase in lymphocyte and eosinophil counts is associated with improved survival. Ann Oncol. 2013;24(6):1697–1703.
34. Ascierto PA, Simeone E, Sileni VC, et al. Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort. J Transl Med. 2014;12(1):116.
35. Weber JS, Dummer R, de Pril V, et al. Patterns of onset and resolution of immune–related adverse events of special interest with ipilimumab. Cancer. 2013;119(9):1675–1682.